glp 1 free trial GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 FDA approves Lilly's Foundayo™ (orforglipron),

A healthcare provider may prescribe these drugs for people not meeting these criteria, but doing so would be considered off-label

In addition to its local gut functions, the gut microbiota also produces bioactive metabolites, such as short-chain fatty acids (SCFAs), lipopolysaccharides (LPS), secondary bile acids, and generates precursors of uremic toxins, targeting systemic distant organs such as the liver, kidney, and cardiovascular system [5, 6]

The weight loss potential for each patient can vary

GLP-1 agonists, including the medication we compound ourselves, have shown promising results for weight loss in clinical trials

Decreases in OSA would be expected to lead to improvements in sleep quality and thus mood and productivity

GLP-1R reporter assay was performed twice with triplicates for each test article concentration